Mersana slashes half its staff, loses $400M in value after trial failure


Mersana Therapeutics Inc. is in free fall after a cancer drug met a surprise failure in a clinical trial.

Previous Shoma’s $10M judgment against local developer restored by court
Next Portland Clinic nixes building plans, seeks new space downtown